Fig. 5.

Inhibition of exosome shedding and enhanced CDC susceptibility induced by rapamycin, indometacin, and U18666A. OCI-Ly1 Lymphoma cells (5 × 10⁷) were exposed to inhibitors of exosome synthesis or release, exosomes were harvested after a 24 h, and yields were measured by both AChE activity (A) and flotillin-2, with GAPDH as control of protein content in treated parental cells (B). Significant differences (repeated measure ANOVA with Bonferroni's post test) are marked (for equivalent results in the cell lines Balm3 and Su-DHL-4, see Fig. S6). (C) Concomitant incubation of lymphoma cells with inhibitors and rituximab in the presence of 10% active human complement increased the cytolytic activity of the antibody in a dose-dependent manner. Lymphoma cells were exposed to rituximab in the presence of complement. The differences in viabilities between experimental samples (with inhibitors) and controls reached significance at rituximab concentrations above 10⁻¹⁰ M (two-way ANOVA with Bonferroni's post test).